NASDAQ$MRVI
Maravai LifeSciences Holdings Inc. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year, with base business revenues, excluding COVID-19 related CleanCap® revenues, up 67% in the fourth quarter.
Maravai LifeSciences reported a decrease in revenue for the fourth quarter, driven by a decline in Nucleic Acid Production revenue due to decreased CleanCap demand. However, base Nucleic Acid Production revenue increased significantly. Net income and Adjusted EBITDA also decreased compared to the same period in the prior year.
- Quarterly revenue reached $204.7 million and net income reached $87.4 million.
- Adjusted fully diluted earnings per share (EPS) of $0.35.
- Base Nucleic Acid Production revenue was up 101% over the same period in the prior year.
- Acquired Alphazyme, LLC to add critical enzyme manufacturing capabilities to Maravai’s Nucleic Acid Production Segment.
Headline financials
Revenue & EPS history
Maravai · Revenue · Quarterly
$205M
Revenue by segment
Maravai · $205M total across 2 segments · Q4 2022
- TriLink$189M-10.9%92.5%
- Cygnus$15.4M-3.2%7.5%
Forward guidance
Maravai expects total revenue for 2023 to be in the range of $420.0 million to $460.0 million, including an estimate of $100.0 million of CleanCap revenue. Adjusted fully diluted EPS is expected to be in the range of $0.32 - $0.38 per share.
Tailwinds
- Base business revenues, excluding COVID-19 related CleanCap revenues, expected to grow in excess of 20%.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.2%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+1.1%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+58.9%
Q4 2023
Best reaction
-36.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.4% | +10.9% | +27.5% | |
| Q4 2025 | +9.9% | +13.2% | -12.3% | |
| Q3 2025 | -0.7% | +12.5% | +28.0% | |
| Q1 2025 | -2.4% | -0.9% | +6.6% | |
| Q4 2024 | -6.4% | -13.2% | -31.4% | |
| Q3 2024 | -36.7% | -29.0% | -37.1% | |
| Q2 2024 | -6.7% | -4.3% | -0.4% | |
| Q1 2024 | +10.0% | +17.5% | -3.9% | |
| Q4 2023 | +58.9% | +57.0% | +66.5% | |
| Q3 2023 | -31.3% | -25.0% | -24.3% | |
| Q2 2023 | -3.5% | -10.1% | -5.7% | |
| Q1 2023 | -16.4% | +2.5% | -3.3% | |
| Q4 2022 | +6.9% | +3.2% | -2.4% | |
| Q3 2022 | -11.7% | -13.8% | -15.3% | |
| Q2 2022 | +2.2% | -3.5% | -20.7% | |
| Q1 2022 | +6.1% | -2.9% | +6.7% | |
| Q4 2019 | +1.4% | +1.1% | -9.7% | |
| Q4 2021 | -1.6% | +14.8% | +7.0% | |
| Q3 2020 | -1.7% | -0.4% | +6.3% | |
| Q3 2021 | +1.6% | +3.1% | +10.1% | |
| Q2 2021 | -5.7% | +8.8% | +0.6% | |
| Q1 2020 | +4.0% | +8.6% | +26.5% | |
| Q1 2021 | -4.8% | +2.1% | +13.1% | |
| Q4 2020 | -0.4% | -2.4% | -6.3% | |
| Q2 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro